Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer
Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over…
Continue Reading
-
-
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma
Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from…
Continue Reading -
Tessa Therapeutics Announces New Executive Leadership
Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive…
Continue Reading -
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by…
Continue Reading